Literature DB >> 28191514

Anticoagulant therapy for non-ST-segment elevation acute coronary syndrome in China: A multi-center observational study.

Xiao-Huan Gong1, Jin-Ming Yu1, Yong Mao1, Da-Yi Hu2.   

Abstract

OBJECTIVE: To assess the anticoagulant therapy for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in China and to offer the rationale for establishing reasonable strategies to improve the prognosis of NSTE-ACS.
METHODS: A total of 1,502 patients with NSTE-ACS were recruited from 28 third-grade hospitals distributed in 14 provinces and cities in China from December 2009 to December 2011. The strategies for diagnosis and treatment, decided by each hospital respectively, were used for further analysis and comparison of medication, percutaneous coronary intervention (PCI), and end points for efficacy and safety assessment at 9 and 30 days following PCI.
RESULTS: A lower incidence rate (P < 0.05) was noted for efficacy and safety in patients with unstable angina (UA) than those with non-ST-segment elevation myocardial infarction (NSTE-MI). The prescription rate of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, PCI, and single medication was 0.61%, 66.42%, 30.61%, 69.64%, and 70.74%, respectively.
CONCLUSION: Compared with NSTE-MI, UA is featured with better prognosis, less severity, and different outcome. However, in clinical practice, the therapies for NSTE-MI and UA show no differences, which deserves great attention. In China, the most common anticoagulant therapies for NSTE-ACS are single medication, mainly based on LMWH and PCI.

Entities:  

Keywords:  ST-segment elevation; acute coronary syndrome; anticoagulant; myocardial infarction; unstable angina

Year:  2016        PMID: 28191514      PMCID: PMC5290911          DOI: 10.1515/jtim-2016-0006

Source DB:  PubMed          Journal:  J Transl Int Med        ISSN: 2224-4018


  7 in total

Review 1.  [Fondaparinux in the treatment of acute coronary syndromes].

Authors:  Li Song; Hong-bing Yan
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2010-05

2.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; James Patrick Zidar
Journal:  J Am Coll Cardiol       Date:  2011-05-10       Impact factor: 24.094

3.  [Comparison of current clinical practice and guideline application in therapies of ACS: findings from the Multi-central Collaborative Group on Chinese registry of acute coronary events].

Authors: 
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2005-09

4.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

Authors:  Salim Yusuf; Shamir R Mehta; Susan Chrolavicius; Rizwan Afzal; Janice Pogue; Christopher B Granger; Andrzej Budaj; Ron J G Peters; Jean-Pierre Bassand; Lars Wallentin; Campbell Joyner; Keith A A Fox
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

5.  A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.

Authors:  Maarten L Simoons; Inge W G Bobbink; Jean Boland; Martin Gardien; Peter Klootwijk; Anthonie W A Lensing; Witold Ruzyllo; Victor A W M Umans; Alec Vahanian; Frans Van De Werf; Uwe Zeymer
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

6.  Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; William E Brady; Harvey D White; Keith A A Fox; Joanne Palmisano; Karen E Ramsey; David W Bilheimer; Eldrin F Lewis; M Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  Eur Heart J       Date:  2004-10       Impact factor: 29.983

7.  [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].

Authors:  Zhen-guo Zhai; Chen Wang; Yan-mei Liu; Zhi-qiang Qin
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2004-06
  7 in total
  3 in total

Review 1.  Circular RNAs in thoracic diseases.

Authors:  Fan Yang; Ping Zhu; Jintao Guo; Xiang Liu; Sheng Wang; Guoxin Wang; Wen Liu; Shupeng Wang; Nan Ge
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Expression of p53 in myocardium following coronary microembolization in rats and its significance.

Authors:  Yu-Han Sun; Qiang Su; Lang Li; Xian-Tao Wang; Yuan-Xi Lu; Jia-Bao Liang
Journal:  J Geriatr Cardiol       Date:  2017-05       Impact factor: 3.327

3.  Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention.

Authors:  Zhi-Zhong Li; Ying Tao; Su Wang; Cheng-Qian Yin; Yu-Long Gao; Yu-Tong Cheng; Zhao Li; Chang-Sheng Ma
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.